Agonistic anti-CD40 IgG2 antibody YH003

YH003 is a promising recombinant humanized agonistic CD40 IgG2 monoclonal antibody that has shown good safety and preliminary efficacy in phase I clinical studies when used in combination with PD-1 monoclonal antibody (mAb) for patients with advanced solid tumors. Notably, there were no cytokine storm-related adverse reactions or significant transaminase elevation or hepatic toxicity observed.

Clinical Progress
Currently, a multi-regional phase II clinical study is underway to evaluate the antitumor activity of YH003 in combination with toripalimab (PD-1 mAb) with or without chemotherapy in subjects with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).

Trial #:YH003004
NCT #:NCT05031494

In a phase I clinical trial conducted in Australia, YH003 was combined with the anti-PD-1 mAb Toripalimab from Junshi Biosciences and demonstrated excellent safety and efficacy. As of April 3, 2022, the study had enrolled a total of 26 subjects with advanced solid tumors who had either progressed after standard treatment or were intolerant to it. The patients had received a median of three lines of treatments (range: 1-7 lines), and eleven out of the twenty-six enrolled patients had previously undergone immunotherapy (PD-1, PD-L1 or PD-1/CTLA-4 bispecific antibody). During dose escalation from 0.03 mg/kg to 3.0 mg/kg, YH003 did not reach its maximum tolerated dose. Only two patients experienced Grade 3 adverse events related to YH003 – neutropenia and transaminase elevation – while no ≥ Grade 4 AE occurred. In all subjects, only one dose-limiting toxicity event was observed without any drug-related serious adverse events occurring. Of the nineteen radiographically evaluable subjects, three achieved partial response (ORR =15.8%) while four showed stable disease (DCR =36.8%). The primary endpoint was met successfully as recommended phase II dose (RP2D) was determined to be at a dosage level of 0.3 mg/kg for further studies on this combination therapy’s efficacy against advanced solid tumors that have failed standard treatment options or are intolerant towards them.

Trial #:YH003002
NCT #:NCT04481009

We also obtained the IND approval from the NMPA for a Phase I clinical trial of YH003 in advanced solid tumor patients in China.

A multicenter, open-label, international phase I dose escalation study of the safety, tolerability and pharmacokinetics of YH003 (CD40 mAb) + YH001 (CTLA-4 mAb) + PD-1 mAb (pembrolizumab) in subjects with advanced solid tumors. It is being conducted in Australia, China and other countries.
Trial #:YH003005
NCT #:NCT05176509

A phase II clinical trial of a combination therapy YH003 (CD40 mAb) + PD-1 mAb (pembrolizumab) + standard chemotherapy (albumin-bound paclitaxel) in China as the first-line treatment for mucosal melanoma
Trial #:YH003006
NCT #:NCT05420324

Preclinical studies have yielded promising results for YH003:

1. In the B-hCD40 syngeneic model, YH003 demonstrated a superior safety profile compared to selicrelumab at doses of 0.3 mg/kg, 3 mg/kg or 30 mg/kg as it did not show any hepatotoxicity.

2.YH003 exhibited strong dose-dependent efficacy in multiple tumor models when administered alone or in combination with PD-1 antibodies. In fact, complete tumor response was observed with combination treatment of YH003 and PD-1 antibody during preclinical studies.

3.The IgG2 subtype design of YH003 avoids the antibody-dependent cellular cytotoxicity (ADCC) effect which leads to an expanded treatment window and longer in vivo half-life.

CD40 Target
The CD40 target is crucial for effective tumor immunotherapy as it promotes activation of innate immune cells such as dendritic antigen presenting cells (DCs), and positively regulates effector activity of anti-tumor T cells. Studies have shown that CD40 activation can transform cold tumors lacking immune cell infiltration into hot tumors that respond well to immunotherapy. To overcome limitations associated with traditional in vitro drug screening processes, early stage development for YH003 involved high-throughput in vivo efficacy and safety studies to ensure optimal therapeutic outcomes are achieved while minimizing adverse effects in patients.

Contact us for partnership: [email protected]

Poster Downloads

ASCO 2024: A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC)

ESMO2023: Phase I open-label, dose escalation and expansion study of YH003 in combination with Toripalimab in patients with advanced solid tumors

ASCO2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors

Related News

November 1, 2022 | Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence
April 7, 2022 | Biocytogen Subsidiary Eucure Biopharma Completes First Patient Dosing for Phase I Clinical Trial of YH003 (Anti-CD40 mAb) Triple Combination Therapy
December 8, 2021 | Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia
November 2, 2021 | Biocytogen/Eucure Biopharma’s YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration

Back to top